Literature DB >> 2116314

Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease patient.

A Casonato1, F Fabris, A Girolami.   

Abstract

Our study shows that the thrombocytopenia described in type IIB von Willebrand's disease (vWd) after 1-desamino-8-D-arginine vasopressin (DDAVP) infusion is, at least partially, a pseudothrombocytopenia. There was a discrepancy in platelet counts in blood anticoagulated with EDTA (less than 10 x 10(3)/microliters) or citrate (55 x 10(3)/microliters) in one patient with type IIB vWd and chronic thrombocytopenia (80 x 10(3)/microliters) after DDAVP infusion. Furthermore, DDAVP induced a normalization of patient's prolonged bleeding time. Spontaneous platelet aggregation (SPA) observed in platelet-rich plasma before DDAVP infusion was inhibited completely by monoclonal antibodies which block binding of fibrinogen, vWf and fibronectin to GPIIb-IIIa. SPA was partially inhibited by a monoclonal antibody which blocks the binding of vWf to GPIb. After DDAVP, in contrast, SPA partially persisted in the presence of anti-GPIIb-IIIa monoclonal antibodies but was completely inhibited by anti-GPIb monoclonal antibody. Therefore GPIb and GPIIb-IIIa complex seem to play a different role in SPA before and after DDAVP infusion into type IIB vWd.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2116314     DOI: 10.1111/j.1600-0609.1990.tb00412.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Pseudothrombocytopenia in a child with the acquired immunodeficiency syndrome.

Authors:  V K Wong; R Robertson; G Nagaoka; E Ong; L Petz; E R Stiehm
Journal:  West J Med       Date:  1992-12

2.  Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B.

Authors:  C Mauz-Körholz; U Budde; H Kruck; D Körholz; U Göbel
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

Review 3.  Current management of von Willebrand's disease.

Authors:  G Castaman; F Rodeghiero
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

4.  Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue.

Authors:  Alessandra Casonato; Viviana Daidone; Eva Galletta; Antonella Bertomoro
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.